STOCKS TELEGRAPH

Tag: AVDL stock

  • Shares Rally Up For Avadel (AVDL) As Court Rules Favorably

    Shares Rally Up For Avadel (AVDL) As Court Rules Favorably

    Following a recent favorable court decision, Avadel Pharmaceuticals plc (NASDAQ: AVDL) stock is enjoying a notable increase this morning, rising 17.89% to $15.22 as of the last check. The U.S. District Court for the District of Columbia ruled in favor of the FDA, thus dismissing Jazz Pharmaceuticals’ complaint under the Administrative Procedure Act.

    Avadel’s LUMRYZ, the first single-dose oxybate medication for narcoleptics who suffer from cataplexy or severe daytime sleepiness, was challenged in court after the FDA approved it. This decision upholds the FDA’s stance that LUMRYZ is clinically superior than Jazz’s twice-nightly oxybate medications, ensuring the continuation of LUMRYZ’s authorized status.

    Legal Background: Jazz Pharmaceuticals’ Challenge

    After LUMRYZ received a seven-year Orphan Drug Exclusivity (ODE) grant and final FDA clearance in May 2023, Jazz Pharmaceuticals sued the FDA, claiming the approval violated the Orphan Drug Act. Avadel CNS Pharmaceuticals, LLC (“Avadel CNS”) entered the action in support of the FDA, arguing that LUMRYZ’s approval should be maintained due to its clinical superiority in minimizing the need for patients to get up throughout the night to take a second dosage.

    FDA’s Findings on Clinical Superiority

    In its approval, the FDA emphasized LUMRYZ’s ability to provide a once-nightly dosing regimen, a notable advancement over the twice-nightly requirement of existing oxybate treatments. This shift reduces nocturnal awakenings, offering patients with narcolepsy an improved treatment option that minimizes sleep disturbances.

    Recently, in October 2024, the FDA extended this exclusivity for pediatric patients aged seven and older, recognizing that LUMRYZ’s single-dose schedule significantly contributes to patient care by supporting uninterrupted sleep, unlike twice-nightly regimens.

    Impact of the Ruling on Avadel and the Narcolepsy Community

    This court decision affirms LUMRYZ’s unique role in narcolepsy treatment and reinforces its market position, permitting Avadel to move forward with its commercial rollout. The ruling also highlights the FDA’s recognition of LUMRYZ’s dosing schedule as a significant contribution to patient care within the narcolepsy community.

    With Orphan Drug Exclusivity intact, Avadel (AVDL) is positioned to expand LUMRYZ’s presence, offering a clinically advanced solution for those managing cataplexy and excessive daytime sleepiness.

  • Avadel Pharmaceuticals PLC (AVDL) on a Roller-Coaster Ride After Announcing Data Presentation at AAN Meeting

    On April 25, Avadel Pharmaceuticals PLC (AVDL) announced its interim data presentation at the 2022 American Academy of Neurology (AAN) Annual Meeting. Following the early morning announcement, AVDL stock collapsed to register its new 52-week low of $4.2100 in the regular trading session. After plunging down by a huge 36.02%, the stock rebounded in the after-hours to recover 26.01%. Thus, the stock then reached a value of $5.3050 per share in the after-hours session.

    Source: Issuewire

    AVDL’s Data Presentation

    The company announced the interim data from its ongoing open-label RESTORE study of its lead drug candidate FT218 which it plans to present at the meeting. AAN meeting is currently taking place virtually and will end on April 26, 2022.

    FT218 is an investigational drug designed for the treatment of excessive daytime sleepiness (EDS) or cataplexy associated with narcolepsy. The interim data presentation includes questionnaires evaluating different aspects of the drug. One evaluates the preference for a once and twice-nightly-dosing regimen of the drug. And another assesses experiences with a second nightly dose after switching from oxybates to FT218. As per the interim results, preferences for the once bedtime dose were noted over the twice-nightly regimen. Moreover, the data also provided insight into challenges patients face with the second, middle-of-the-night dose which FT218 has the potential to eliminate.

    What Happened with AVDL?

    Following the announcement, AVDL stock entered a roller-coaster ride with huge losses and a comeback. The stock declined to a new 52-week low soon after the news was shared which garnered investors’ interest. Presenting a nice buying opportunity, investors capitalized on the dip and started buying it after the stock plunged to new lows. Thus, the dip ultimately resulted in a comeback of the stock in the after-hours, helping it recover most of its day’s losses.

    Market Opportunity

    Sleep disorder treatment is a growing market as the hectic lifestyle in the modern world is full of stress which triggers sleep disorders. Furthermore, treating sleep disorders is essential to continuing a normal life as the disorders cause a negative impact on all aspects of life ranging from mental, physical, social to emotional.

    Currently, the sleep disorder treatment market is forecasted to register a CAGR of 8.4% from 2021 to 2028. The market is expected to reach $ 14.732.08 million by the end of the forecast period with the increased prevalence of sleep disorders being the precursor to its growth.

    Conclusion

    With a growing market opportunity, AVDL’s lead candidate after being granted Orphan Drug Designation is currently undergoing the RESTORE study. While investors were not much impressed by the interim data from the trial, it is still in the very initial stages.

    On the other hand, after plunging down big time, AVDL stock rebounded efficiently in the after-hours on Monday.